Enzychem Lifesciences' Growth Continues in US, Adds Jeff Clark as New Chief Licensing Officer

Saturday, June 30, 2018 Lifestyle News
Email Print This Page Comment bookmark
Font : A-A+

ENGLEWOOD CLIFFS, N.J., June 29, 2018 /PRNewswire/ -- On May 14th, Enzychem Lifesciences Corp.

(KOSDAQ: 183490), one of the fastest growing life sciences company in South Korea's KOSDAQ Stock Exchange, hired Jeff Clark, MD, JD, a physician and patent attorney, as its Chief Licensing Officer.

By serving as

Chief Licensing Officer, Dr. Clark will work on strengthening the worldwide Intellectual Property of the company and spearhead global licensing deals and agreements.  Enzychem is conducting three US clinical trial programs for Chemotherapy Induced Neutropenia (CIN), Chemoradiation Induced Oral Mucositis (CRIOM; granted Fast Track designation by FDA) and Acute Radiation Syndrome (ARS; granted Orphan Drug designation by FDA).  Alongside these clinical programs, Dr. Clark's hiring shows that Enzychem is committed in exploring potential licensing deals with US pharma companies. After joining the company, Dr. Clark established a Global Licensing Team under his leadership, composed of key physicians, scientists, lawyers and other staff and launched a comprehensive plan to strengthen Enzychem's assets, new drug development, and clinical programs. 

Previously, Dr. Clark worked as a patent attorney and litigation (products liability) associate at the global law firm, DLA Piper LLP (US).  There, he counseled life science and biotech clients in all aspects of patent law and defended pharmaceutical and medical device companies in multidistrict product liability litigation.  Dr. Clark was a clinical fellow in the Cardiovascular Research Center, Department of Cardiology, at Massachusetts General Hospital and in the Molecular and Vascular Medicine, Renal Unit, at Beth Israel Deaconess Medical Center, both in Boston.   Dr. Clark has authored and co-authored several scientific publications in peer-reviewed journals and has presented work at the American Society of Nephrology Renal Week conference.

Dr. Clark received his B.A. magna cum laude from Bowdoin College, M.D. with Distinction in Research from the University of Rochester School of Medicine and J.D. from Boston College Law School.  He has been named as a New England Rising Star in Intellectual Property by Super Lawyers and received a USPTO Patent Pro Bono Certificate in 2017 for services provided to the Patent Pro Bono Program of New England.

About Enzychem Lifesciences Corporation

Enzychem Lifesciences Corp. (KOSDAQ:183490) is a global new drug development biopharmaceutical company founded in 1999.  With R&D driven approach and corporate mission of "Saving Human Lives by Overcoming Unmet Medical Needs", Enzychem is developing innovative treatments which can address significant unmet medical needs. Enzychem is one of the fastest growing life sciences company by market capitalization in South Korea's KOSDAQ Stock Exchange. The company is headquartered in Seoul, South Korea.

For more information on Enzychem Lifesciences, visit http://www.enzychem.com/

This discussion may include predictions, estimates or other information that might be considered forward-looking. While these forward-looking statements represent Enzychem's current judgment on what the future holds, they are subject to risks and uncertainties that could cause actual results to differ materially. You are cautioned not to place undue reliance on these forward-looking statements, which reflect our opinions only as of the date of this announcement. Please keep in mind that Enzychem is not obligating itself to revise or publicly release the results of any revision to these forward-looking statements in light of new information or future events.

The information included in this press release concerns a drug use that has not been approved by the Food and Drug Administration.


Cision View original content:http://www.prnewswire.com/news-releases/enzychem-lifesciences-growth-continues-in-us-adds-jeff-clark-as-new-chief-licensing-officer-300674823.html

SOURCE Enzychem Lifesciences Corporation

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store